The stock is likely to react negatively to the EPS miss and lack of revenue traction; monitor for trial enrollment updates as near-term catalysts, but expect continued pressure until meaningful revenue or funding milestones are achieved.
Price Chart
Executive Summary
Nexalin Technology (NXL) reported a Q4 2025 EPS miss of -27% versus consensus, with actual EPS of -$0.13 versus an estimate of -$0.10. The company provided no revenue guidance and instead focused on advancing its HALO™ Clarity clinical trial for insomnia, marking a strategic pivot toward regulatory development rather than commercial performance.
Key Financial Metrics
Key Facts
- Q4 2025 EPS was -$0.13, missing consensus by -27% (estimated: -$0.10)
- Reported revenue was $15K, though no actual revenue figure was disclosed in the release
- No financial guidance or revenue updates were provided
- Company is advancing a pivotal clinical trial for its HALO™ Clarity device targeting FDA De Novo classification
- Trial enrollment expected to begin in Q2 2026, conducted in partnership with Lindus Health
Financial Impact
EPS miss of 27% below expectations; minimal revenue base ($15K consensus)
Risk Factors
- High risk of clinical trial delays or failure
- Dependence on regulatory approval via uncertain De Novo pathway
- Limited financial runway without clear funding update
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3279086 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | EFFECT | $2.35 | awaiting T+20 | — | $1.64 (+30.21%) |
Oct 8, 2026 19d ago | S-1/A | $3.63 | awaiting T+20 | — | $1.64 (+54.82%) |
Oct 1, 2026 26d ago | 8-K | $5.73 | awaiting T+20 | — | $1.64 (−71.38%) |
Oct 1, 2026 26d ago | 8-K | $5.73 | awaiting T+20 | — | $1.64 (−71.38%) |
Sep 2, 2026 7w ago | 8-K | $5.36 $4.28 | ▼ −20.15% | ▼ −19.03% | $1.64 (−69.40%) |
Aug 27, 2026 8w ago | 8-K | $0.2548 $0.1463 | ▼ −42.57% | ▼ −42.60% | $1.64 (+543.64%) |
Aug 17, 2026 10w ago | 8-K | $0.3400 $0.1617 | ▲ +52.45% | ▲ +50.47% | $1.64 (−382.35%) |
Jun 10, 2026 19w ago | Press Release | $0.4590 $0.4607 | ▲ +0.37% | ▼ −3.70% | $1.64 (+257.30%) |
May 19, 2026 23w ago | 8-K | $0.3350 $0.3680 | ▲ +9.85% | ▲ +9.11% | $1.64 (+389.55%) |
May 19, 2026 23w ago | Press Release | $0.3210 $0.3930 | ▲ +22.43% | ▲ +21.44% | $1.64 (+410.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers